Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Neuroblastoma 2Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Lymphoma 1Hepatoblastoma 1

Interventions

Topotecan 2Ifosfamide 2Etoposide 2trioctyl phosphine oxide 1indolepropanol phosphate 1imetelstat 1Vincristine 1Transplantation 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Pentetic Acid 1Minocycline 1Melphalan 1Heparin 1Glutamine 1GRN163L peptide 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neuroectodermal Tumors, Primitive, Peripheral × imetelstat × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡